On May 23, 2024, the 2024 working plan was published by the Spanish Network of HTA Agencies (RedETS). Topics in cardiovascular, diagnostic imaging, e-health, endoscopy, ENT, extracorporeal treatments, ICU/OR, in-vitro diagnostics, interventional radiology, men’s health, neurology and neurosurgery, neuromodulation, obstetrics and gynecology, orthopedics, peripheral vascular, pulmonary and airways, radiology, radiotherapy, robotic surgery, spine, surgical procedures, and some other fields are included in the plan.

On May 23, 2024, NHS England and the National Institute for Health and Care Excellence (NICE) launched a joint consultation on their proposed rules-based, integrated, and predictable pathway for MedTech in the NHS. The five key elements of the pathway are pre-authorization (horizon scanning and engagement), authorization (regulatory approval), evaluation and guidance (including the NICE guidance programs), commercial and commissioning (both national and integrated care board levels), and scaled adoption. The deadline for submitting comments is August 15, 2024.

On May 14, 2024, the Dutch Healthcare Authority (NZa) published another update of the 2024 Digital Care Funding Guide, which describes the possibilities for funding digital care depending on the healthcare sector, including new funding for Integrated Care Transformation Plans and the implementation of a novel platform for the assessment of innovative digital applications and/or technologies.

MTRC developed an analytical White Paper with a summary of key market access elements of EU5 countries, including stakeholders, payment mechanisms, innovative payment schemes, funding, and the role of HTA for in-vitro diagnostic tests.

On May 17, 2024, the French National Authority for Health (HAS) announced the start of the application period for evaluating procedures and IVD tests to be included in the 2025 HAS working program.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of booster vaccination against meningococci of serogroup C, reduction of antibiotic resistance, and dual pilot structure for diagnosis clarification in centers for rare diseases.

The application window for changes in the Swiss classification of surgical procedures (CHOP) will open on June 3, 2024. The eligible applicants can submit applications until September 15, 2024.

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that forty-eight applications for innovation funding of healthcare research projects were accepted.

On May 1, 2024, the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV) updated several articles of the Nomenclature. New procedure codes were introduced in pulmonary, endoscopy, and in-vitro diagnostic fields.

Women's health hubs comprise the new model of care outlined by the Department of Health and Social Care in the Women's Health Strategy (2022). The hub model aims to improve access to and experiences of care, improve health outcomes for women, and reduce health inequalities. In April 2024, NHS England published guidance to local commissioners, Integrated Care Boards (ICB). It requires that by the end of December 2024, at least one hub is operational in each ICB area and provides all core services.

On May 4, 2024, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique (SUT). Three new MedTech field codes were introduced to relevant Annexes of the SUT, including FAST Ultrasonography; transcutaneous pacemaker application, and critical patient bed and follow-up in the emergency department.

On April 25, 2024, the Ministry of Labor, Health, and Solidarity published an Order in the Official Journal of the French Republic setting the tariffs for digital medical devices with therapeutic functions covered within the early digital support (PECAN) scheme. The tariff for the manufacturer will include an initial lump sum of €435 per patient billable for up to 3 months and a subsequent monthly package of €38.30. The maximum amount of financial compensation is €780 per year per patient.